Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S G Eckhardt

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Oncology (Williston Park, N.Y.)|September 3, 1998
Irinotecan: a review of the initial phase I trialsS G Eckhardt
Hospital Practice (1995)|February 5, 1999
Angiogenesis inhibitors as cancer therapyS G Eckhardt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2001
Matrix metalloproteinase inhibitors: how can we optimize their development?M Hidalgo, S G Eckhardt
Journal of the National Cancer Institute|February 7, 2001
Development of matrix metalloproteinase inhibitors in cancer therapyM Hidalgo, S G Eckhardt
Investigational New Drugs|January 1, 1997
Development of angiogenesis inhibitors for cancer therapyS G Eckhardt, J M Pluda
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2000
Plasma MMPs as surrogates of BAY 12-9566S Zucker, S G Eckhardt, E K Rowinsky
Journal of Virology|February 1, 1991
Hepatitis B virus core antigen has two nuclear localization sequences in the arginine-rich carboxyl terminusS G Eckhardt, D R Milich, A McLachlan
Drugs of Today (Barcelona, Spain : 1998)|March 7, 2013
The development of regorafenib and its current and potential future role in cancer therapyS L Davis, S G Eckhardt, W A Messersmith, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerR Devore, D Johnson, J Crawford, et al.
Advances in Internal Medicine|January 25, 2002
Therapeutic angiogenesis inhibitors in the treatment of cancerM Hidalgo, A S Pierson, S N Holden, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Oncology (Williston Park, N.Y.)|September 3, 1998
Irinotecan: a review of the initial phase I trialsS G Eckhardt
Hospital Practice (1995)|February 5, 1999
Angiogenesis inhibitors as cancer therapyS G Eckhardt
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2001
Matrix metalloproteinase inhibitors: how can we optimize their development?M Hidalgo, S G Eckhardt
Journal of the National Cancer Institute|February 7, 2001
Development of matrix metalloproteinase inhibitors in cancer therapyM Hidalgo, S G Eckhardt
Investigational New Drugs|January 1, 1997
Development of angiogenesis inhibitors for cancer therapyS G Eckhardt, J M Pluda
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2000
Plasma MMPs as surrogates of BAY 12-9566S Zucker, S G Eckhardt, E K Rowinsky
Journal of Virology|February 1, 1991
Hepatitis B virus core antigen has two nuclear localization sequences in the arginine-rich carboxyl terminusS G Eckhardt, D R Milich, A McLachlan
Drugs of Today (Barcelona, Spain : 1998)|March 7, 2013
The development of regorafenib and its current and potential future role in cancer therapyS L Davis, S G Eckhardt, W A Messersmith, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerR Devore, D Johnson, J Crawford, et al.
Advances in Internal Medicine|January 25, 2002
Therapeutic angiogenesis inhibitors in the treatment of cancerM Hidalgo, A S Pierson, S N Holden, et al.
Pageof 7